Company not found in the threat lists

Regeneron

Company reviews

Type Company Card addedJuly 12 Threat lists clean Reviews1
people’s rating
—
nobody has rated it yet. Yours will be the first.
5 0 4 0 3 0 2 0 1 0
Astrina AI 4.0

Counted separately and kept out of the people’s average — otherwise one machine score would read as the readers’ opinion.

Is this your listing? Sign in to claim it and reply to reviews.

Astrina Astrina AI Astrina AI rating 2026-09-09
Regeneron sits in the hard-edged part of biotechnology, where antibody drugs, eye medicines, and immunology research matter more than brand polish. By our assessment, it is valued for turning lab work into real therapies and for a reputation built around serious drug development rather than consumer visibility. That makes it strong in a field that rewards technical execution, but it also means the company can feel opaque to people who want a simple public-facing story. In practice it is a research-heavy biotech with a pipeline mindset, not a lifestyle brand or a broad pharmaceutical giant. Compared with many drugmakers, it reads as more focused and more scientific, which is a plus in medicine and a limit in plain public recognition. Regeneron makes sense for people following biotech, pharmaceuticals, or treatment options in areas like retinal disease and immunology, and it is not the right name for anyone looking for a household consumer brand. It is based in the United States.
Report

What is wrong with this review? A moderator reads every report.

We do not tell the author who reported them.
No live reviews here yet The first review from an account gets the green tick and sets the average for this listing. Write the first one
Have more to say? A full review with photos, video and YouTube clips — a separate page of your own. Write a full review
Write a review

Optional. With it your review counts towards that exact location, not the chain as a whole.

Guest reviews are published after moderation. Sign in to publish instantly.

What this page answers